Aerpio Pharmaceuticals Inc (ARPO)

2.2  -0.02 (-0.9%)

After market: 2.28 +0.08 (+3.64%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ARPO. ARPO was compared to 198 industry peers in the Pharmaceuticals industry. ARPO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ARPO does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ARPO has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -49.49%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

ARPO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

There is no outstanding debt for ARPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

ARPO has an Altman-Z score of 22.17. This indicates that ARPO is financially healthy and has little risk of bankruptcy at the moment.
There is no outstanding debt for ARPO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.17
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

ARPO has a Current Ratio of 16.94. This indicates that ARPO is financially healthy and has no problem in meeting its short term obligations.
ARPO has a Quick Ratio of 16.94. This indicates that ARPO is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 16.94
Quick Ratio 16.94

More info and screens

1

3. Growth

3.1 Past

ARPO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -355.56%.
The Revenue for ARPO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-355.56%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-139.13%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-100%

3.2 Future

The Earnings Per Share is expected to grow by 14.84% on average over the next years. This is quite good.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y33.81%
EPS Next 2Y6.46%
EPS Next 3Y34.35%
EPS Next 5Y14.84%
Revenue Next Year-100%
Revenue Next 2Y-56.22%
Revenue Next 3Y-41.69%
Revenue Next 5Y-14.87%

3.3 Evolution

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARPO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ARPO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -3.12

4.3 Compensation for Growth

A more expensive valuation may be justified as ARPO's earnings are expected to grow with 34.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.46%
EPS Next 3Y34.35%

More info and screens

0

5. Dividend

5.1 Amount

ARPO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Aerpio Pharmaceuticals Inc

NASDAQ:ARPO (8/26/2021, 7:07:55 PM)

After market: 2.28 +0.08 (+3.64%)

2.2

-0.02 (-0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap104.85M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.49%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 16.94
Quick Ratio 16.94
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-355.56%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y33.81%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y